Core Viewpoint - Haier Biomedical's Q1 revenue reached 688.99 million, a year-on-year increase of 0.30%, indicating a return to normal business development despite challenges in the market [2][3]. Revenue Summary - Total revenue for Q1 2025 was 688.99 million, compared to 686.91 million in the same period last year, reflecting a growth of 0.30% [3]. - Net profit attributable to shareholders decreased by 19.88% to 110.26 million, while the net profit after deducting non-recurring gains and losses fell by 25.38% to 99.17 million [3]. - Operating cash flow decreased significantly by 51.79% to 37.22 million [3]. - Basic and diluted earnings per share both dropped by 20.45% to 0.35 yuan [3]. Business Segment Performance - The Life Sciences segment generated revenue of 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter [3]. - The Medical Innovation segment reported revenue of 332 million, down 0.61% year-on-year but up 24.26% quarter-on-quarter [3]. Growth Drivers 1. Non-storage new industries maintained high growth, with revenue share at 44%, increasing by 13.92% year-on-year and 27.35% quarter-on-quarter, driven by growth in plasma consumables, medication automation, laboratory consumables, and instruments [4]. 2. Domestic scenario solutions continued to expand, with domestic market revenue at 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, enhancing brand strength and competitiveness [4]. 3. The overseas market showed signs of recovery with revenue of 204 million, a year-on-year increase of 9.88% and a quarter-on-quarter increase of 8.99%, reversing the decline seen in 2024 [4]. Future Industry Layout - Haier Biomedical is actively expanding into future industries such as CGT and blood management, launching an intelligent fully automated cell culture workstation and enhancing blood supply efficiency through AI and smart blood management systems [5].

Core Viewpoint - The company maintains a positive outlook on its operational performance and future growth despite challenges in stock price and market conditions [1][2][3]. Financial Performance - In 2024, the company achieved a revenue of 81.76 billion yuan, representing a year-on-year increase of 2.67% [31]. - The net profit attributable to shareholders was 21.93 billion yuan, up 23.25% year-on-year [31]. - The net profit excluding non-recurring gains was 20.60 billion yuan, reflecting a 13.47% increase compared to the previous year [31]. Operational Insights - The company reported a significant decrease in operating cash flow, primarily due to changes in customer payment terms and increased cash outflows for imported goods [1]. - The increase in accounts receivable indicates a potential relaxation of credit policies to boost sales [1]. - Inventory levels rose due to slower sales of human albumin and increased reserves of imported albumin [1]. Market Position and Strategy - The company is recognized as a leading player in the blood products industry, with a focus on enhancing its return on equity (ROE) through improved asset efficiency and profitability [1][2]. - The company holds a 44% share of its revenue from imported human albumin, with significant imports from the US, Spain, and Ireland [2]. - The company is actively pursuing a dual strategy of "expanding plasma sources" and "reducing plasma processing" to enhance its market position [11][27]. Industry Trends - The blood products market is expected to maintain a stable demand, influenced by supply-demand dynamics and healthcare policies [20][24]. - The company is closely monitoring the impact of trade tariffs on its imported products, although the exact effects remain uncertain [3][23]. Future Outlook - The company is committed to ongoing innovation and development in the biopharmaceutical sector, with a focus on clinical research and product diversification [11][27]. - The management expresses confidence in the company's ability to navigate market challenges and enhance shareholder value through strategic initiatives [12][31].

证券代码：688139 证券简称：海尔生物 公告编号：2025-034 青岛海尔生物医疗股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2019 年 7 月 30 日审核同意，并经 中国证券监督管理委员会 2019 年 9 月 20 日下发《关于同意青岛海尔生物医疗股 份有限公司首次公开发行股票注册的批复》（证监许可[2019]1742 号）核准， 同意青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）公开发行人民币普通股不超过 79,267,940 股，每股发行价格为人民币 15.53 元，募集资金总额为人民币 1,231,031,108.20 元，实际到账金额人民币 1,161,576,074.14 元，包括尚未划转的其他发行费用。上述募集资金于 2019 年 10 月 22 日到位，并经安永华明会计师事务所（特殊普通合伙）审验并出具了安 永华明（2019）验字第 61433766_J0 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-033 青岛海尔生物医疗股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 29 日 （二） 股东大会召开的地点：盈康一生大厦 15 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 105 | | --- | --- | | 普通股股东人数 | 105 | | 2、出席会议的股东所持有的表决权数量 | 182,765,940 | | 普通股股东所持有表决权数量 | 182,765,940 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 58.2830 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.2830 | （四） 表决方式是否符 ...

北京市金杜（青岛）律师事务所 关于青岛海尔生物医疗股份有限公司 2024 年年度股东大会之 法律意见书 致：青岛海尔生物医疗股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受青岛海尔生物医疗 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《青岛海尔生物医疗股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 4 月 29 日召 开的 2024 年年度股东大会（以下简称本次股东大会），并就本次股东大会相关 事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 1. 经公司 2024 年第一次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 29 日刊登于巨潮资讯 ...

海尔生物公告，2025年第一季度营业收入6.89亿元，同比增长0.30%。净利润1.1亿元，同比下降 19.88%。 ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has seen a decline of 6.84% in the past month, 2.25% in the past three months, and 3.82% year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (12.68%), United Imaging (10.07%), Aibo Medical (7.84%), Yirui Technology (6.54%), Shengxiang Biology (4.89%), Nanwei Medical (4.79%), Xinmai Medical (4.59%), Haier Biomedical (4.41%), Yahui Long (3.61%), and Bairen Medical (3.46%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - In terms of industry composition, medical consumables account for 47.05%, medical devices for 31.91%, and in vitro diagnostics for 21.04% [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the sample adjustments [2] - Special circumstances may lead to temporary adjustments to the index, such as delisting of samples or corporate actions like mergers and acquisitions [2]

Group 1 - The core viewpoint of the news is that Haier Biomedical's stock performance and financial metrics indicate a relatively low valuation compared to the industry average, despite a decline in net profit [1][3]. - As of April 28, Haier Biomedical's closing stock price was 31.02 yuan, down 2.36%, with a rolling PE ratio of 26.90 times and a total market capitalization of 9.863 billion yuan [1]. - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Haier Biomedical at the 64th position in the industry ranking [1][3]. Group 2 - Haier Biomedical focuses on providing comprehensive digital solutions for life sciences and healthcare, targeting pharmaceutical companies, research institutions, and various healthcare users [2]. - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various laboratory automation equipment [2]. - In 2022, Haier Biomedical received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]. Group 3 - For the fiscal year 2024, Haier Biomedical reported a revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit decreased by 9.71% to 367 million yuan [3]. - The company's gross profit margin stands at 47.99% [3]. - The stock's PE ratio is significantly lower than the industry average, indicating potential undervaluation [3].

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) closed at 2534.82 points, with a trading volume of 4.515 billion yuan, reflecting a slight increase of 0.12% [1] - Over the past month, the CS Internet Medical Index has decreased by 5.58%, while it has increased by 14.02% over the past three months and by 7.06% year-to-date [1] - The index includes representative companies that provide hardware, software, or services for medical informationization and intelligence, with a base date of June 29, 2012, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the CS Internet Medical Index are: Yifeng Pharmacy (6.75%), Daclin (6.71%), Laobaixing (6.14%), Wandong Medical (5.6%), Yixintang (5.58%), Jiuzhoutong (5.43%), Haier Biomedical (5.37%), Lepu Medical (5.32%), Yuyue Medical (5.18%), and Aier Eye Hospital (5.14%) [1] - The market share of the CS Internet Medical Index holdings is divided between Shenzhen Stock Exchange (50.91%) and Shanghai Stock Exchange (49.09%) [1] - In terms of industry composition, the holdings of the CS Internet Medical Index consist of 70.63% in pharmaceuticals and healthcare, 25.60% in information technology, and 3.77% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to calculation and maintenance guidelines [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]